Evidence for a Pathophysiological Role of Keratinocyte-Derived Type III Interferon (IFN lambda) in Cutaneous Lupus Erythematosus

Type I IFNs (IFN alpha/beta) have been shown to have a central role in the pathophysiology of lupus erythematosus (LE). The recently discovered type III IFNs (IFN lambda 1/IL29, IFN lambda 2/IL28a, IFN lambda 3/IL28b) share several functional similarities with type I IFNs, particularly in antiviral immunity. As IFN lambda s act primarily on epithelial cells, we investigated whether type III IFNs might also have a role in the pathogenesis of cutaneous LE (CLE). Our investigations demonstrate that IFN lambda and the IFN lambda receptor were strongly expressed in the epidermis of CLE skin lesions and related autoimmune diseases (lichen planus and dermatomyositis). Significantly enhanced IFN lambda 1 could be measured in the serum of CLE patients with active skin lesions. Functional analyses revealed that human keratinocytes are able to produce high levels of IFN lambda 1 but only low amounts of IFN alpha/beta/gamma in response to immunostimulatory nuclear acids, suggesting that IFN lambda is a major IFN produced by these cells. Exposure of human keratinocytes to IFN lambda 1 induced the expression of several proinflammatory cytokines, including CXCL9 (CXC-motiv ligand 9), which drive the recruitment of immune cells and are associated with the formation of CLE skin lesions. Our results provide evidence for a role of type III IFNs in not only antiviral immunity but also autoimmune diseases of the skin.